Press Releases
Date picker
Category
Results per page
Kancera’s research will be highlighted at this year’s largest conference on cardiovascular diseases
Kancera AB (Nasdaq First North: KAN) today announces that the European Society of Cardiology has selected Kancera's research for its "outstanding quality" which will result in an oral presentation as…
Kancera puts forward KAND145 as a new drug candidate
This is a translation of the press release in Swedish Stockholm 2019-05-02 Kancera AB (Nasdaq First North: KAN) today announces that the company is strengthening its project portfolio by nominating…
Year End Report Kancera AB (publ) 1st January – 31st December 2018
This is a translation of the Year End Report in Swedish published February 20th 2019.
Kancera reports results from analyses of the Fractalkine system in lymphoma patients’ immune cells
This is a translation of a press release in Swedish 2019-01-29 Kancera AB (Nasdaq First North: KAN) today announces that the results of a study of lymphoma patients' immune cells…
Kancera has achieved important intermediate goals prior to the planned start of clinical studies with the drug candidate KAND567
This is a translation from the Swedish press release 2019-01-28 Kancera AB (Nasdaq First North: KAN) today announces that intermediate goals have been achieved prior to the planned start of…
Kancera gains a strong partner for the further development of their HDAC inhibitors
This is a translation of a pressrelease in Swedish from December 3rd 2018. Kancera AB announced today that the company has entered into an Research and Option agreement with Grünenthal,…
INTERIM REPORT FOR KANCERA AB (publ) 1st January – 30th September 2018
Regulatory
PERIOD JAN - SEPTEMBER 2018, AND THIRD QUARTER IN BRIEF• Net sales for the period (January to September) amounted to SEK 0.1 million (SEK 0.1 million) of which the third quarter amounted to…
Kancera AB announces that a letter of intent has been signed with US-based private investor
Here follows a translation of a Swedish press release from November 23th 2018. Kancera announces that terms have been prepared for a shareholders' decision on investment in the company by…
Discovery of how Kancera’s PFKFB3 inhibitor acts against cancer published in a reputable scientific journal
Kancera AB today announced that the article entitled "Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination" has been published by researchers from Karolinska Institutet and Kancera AB in the…
Kancera provides an operational update for the Fractalkine project
Kancera AB (publ) hereby reports on project activities and status for the preparation and implementation of a clinical study in cardiovascular inflammation associated with myocardial infarction. In the cancer area,…